Lumexa Imaging Grows Revenue, But Profit Miss Rattles Investors

RALEIGH, N.C. – March 26, 2026 – Lumexa Imaging (Nasdaq: LMRI) presented a dual narrative to investors today, reporting strong top-line growth and strategic successes for its fourth quarter and full year 2025, while simultaneously revealing a net loss that fell short of Wall Street expectations and triggered a sharp sell-off of its stock.

The outpatient imaging provider announced preliminary full-year 2025 consolidated revenues of $1.023 billion, a 7.8% increase from the prior year. Adjusted EBITDA, a key metric of operational profitability, also saw robust growth, rising 14.6% to $230.2 million. However, the positive operational metrics were overshadowed by a significant earnings per share (EPS) miss. Analysts had forecast a profit, but the company reported a GAAP net loss of $28.7 million for the fourth quarter, or -$0.38 per share, sending the stock plunging by over 27% in premarket trading.

Strategic Wins Drive Record Growth

Company leadership focused on the year's operational achievements, which were significant. The fourth quarter capped a year of expansion and increased demand, particularly for advanced imaging procedures like MRI and CT scans. Consolidated revenues for the quarter climbed 7.9% year-over-year to $267.7 million, while same-center advanced imaging volume surged an impressive 12.7%.

In a statement, CEO Caitlin Zulla highlighted the drivers behind the strong performance. “The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business,” said Zulla. “Strong Adjusted EBITDA growth was driven by advanced imaging volumes, ramping new de novo centers, and our return in-network with a large payer in New Jersey.”

This return to an in-network status in New Jersey was a crucial factor, unlocking pent-up demand and boosting patient volumes in a key market. This, combined with the successful launch of a record number of new imaging centers, painted a picture of a company executing effectively on its core growth strategy.

A Strengthened Foundation: Debt Reduction and Deleveraging

A cornerstone of Lumexa's 2025 story is its aggressive and successful effort to repair its balance sheet. The company announced a two-turn reduction in its debt leverage, bringing it down from 5.5 to 3.5 times its Adjusted EBITDA. This deleveraging was primarily fueled by the strategic use of $406 million in net proceeds from its recent Initial Public Offering (IPO) to pay down debt.

This move is expected to yield substantial long-term benefits, with the company projecting over $50 million in annual cash savings from more favorable interest rates on its refinanced debt. The market's primary credit rating agencies have taken notice of the improved financial stability. In December 2025, both S&P and Moody's upgraded Lumexa's credit rating to B+ and B2, respectively. S&P specifically noted the post-IPO decline in private equity ownership as a credit positive, suggesting a move towards a more conservative financial policy.

This fortified financial position gives Lumexa greater flexibility to continue investing in its growth initiatives without being over-leveraged, a critical advantage in the capital-intensive healthcare sector.

Growth Strategy in Focus: Expansion and Technology

Lumexa's growth wasn't just financial; it was also physical. The company added a record ten new imaging facilities in 2025, consisting of nine newly built (de novo) centers and one acquisition. This expansion was strategically targeted across high-growth markets in New York, South Carolina, and Texas, with the most recent openings in Anderson, South Carolina, and the Cotswold area of Charlotte, North Carolina.

This expansion aligns with the company's plan to open 8-10 new centers annually, either independently or through joint ventures, to capitalize on the ongoing shift of medical procedures from traditional hospitals to more cost-effective and convenient outpatient settings. The company's strategy is bolstered by investments in technology. By deploying AI-enabled software to accelerate scanning times, Lumexa reports it has increased schedule throughput by nearly 40% at some centers, an efficiency it plans to roll out to two-thirds of its network by the end of 2026.

Investor Jitters: Navigating Profitability Concerns

Despite the strong operational performance and strategic deleveraging, the immediate market reaction was harsh. The significant Q4 net loss of $28.7 million, widening from $25.1 million in the prior-year quarter, was the primary catalyst for investor concern. The loss was attributed largely to one-time costs associated with its IPO and debt refinancing, including a $13.5 million loss on extinguishment of debt.

While these costs are not related to core operations, the resulting EPS miss created a disconnect between the company's positive operational narrative and its bottom-line GAAP results. This gap fueled investor uncertainty, leading to the sharp stock decline. However, the longer-term view from institutional investors and analysts appears more optimistic. Several hedge funds increased their positions in Lumexa during the fourth quarter, and analyst price targets remain bullish, with most falling in the $22 to $23 range, suggesting they see the current profitability issues as temporary hurdles.

Looking Ahead: 2026 Outlook and Industry Tailwinds

Looking forward, Lumexa reiterated its full-year 2026 guidance, signaling confidence in its trajectory. The company projects consolidated revenues between $1.045 billion and $1.097 billion and Adjusted EBITDA of $234 million to $242 million. It also initiated guidance for Adjusted EPS of $0.71 to $0.77 per share, indicating a clear path to profitability on a non-GAAP basis.

“Looking ahead, our 2026 outlook reflects continued growth and margin expansion, supported by durable demand tailwinds and the ongoing shift to outpatient care,” Zulla stated. “With a focused strategy centered on same-center growth, geographic expansion, and advanced imaging, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth.”

The company is poised to benefit from powerful industry trends, including an aging population, the development of new drugs requiring diagnostic imaging, and the persistent migration of care away from hospitals. While Lumexa must prove it can translate its top-line growth into consistent GAAP profitability, its strengthened balance sheet and clear strategic focus have laid a foundation to potentially turn a year of mixed results into a platform for future success.